Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis

Stage III metastatic melanomas require adequate adjuvant immunotherapy to prevent relapses. Prognostic factors are awaited to optimize the clinical management of these patients. The magnitude of metastatic lymph node invasion and the BRAFV600 activating mutation have clinical significance. Based on...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Invest Dermatol
Main Authors: Jacquelot, Nicolas, Roberti, María Paula, Enot, David P., Rusakiewicz, Sylvie, Semeraro, Michaela, Jegou, Sarah, Flores, Camila, Chen, Lieping, Kwon, Byoung S., Borg, Christophe, Weide, Benjamin, Aubin, Frangois, Dalle, Stephane, Kohrt, Holbrook, Ayyoub, Maha, Kroemer, Guido, Marabelle, Aurelien, Cavalcanti, Andrea, Eggermont, Alexander, Zitvogel, Laurence
Formato: Artigo
Idioma:Inglês
Publicado: 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6156792/
https://ncbi.nlm.nih.gov/pubmed/26829031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jid.2015.12.042
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares